^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Halaven (eribulin mesylate)

    i
    Company:
    Eisai, Knight Therap, Shenzhen Kexing Pharma
    Drug class:
    Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor
    Related drugs:
    Apply
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (NCT05063786)
    Phase 3
    Spanish Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2 • ER • PIK3CA • PGR
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation
    |
    Halaven (eribulin mesylate) • Aliqopa (copanlisib)
    Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY) (NCT03222856)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/14/2017
    Primary completion :
    10/31/2018
    Completion :
    12/23/2020
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-TNBC) (NCT03424005)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/30/2018
    Primary completion :
    05/03/2028
    Completion :
    05/03/2028
    HER-2 • PD-L1 • PIK3CA
    |
    PD-L1 expression • PIK3CA mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/06/2025
    Initiation :
    08/04/2025
    Primary completion :
    05/17/2027
    Completion :
    05/17/2027
    RIPK1
    |
    Halaven (eribulin mesylate) • tolinapant (ASTX660)
    EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (NCT05619913)
    Phase 2
    Australia New Zealand Gynaecological Oncology G...
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    05/22/2023
    Primary completion :
    03/01/2025
    Completion :
    12/01/2026
    HMGA2
    |
    HMGA2 expression
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (TBCRC 058) (NCT06099769)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    01/20/2025
    Initiation :
    10/18/2023
    Primary completion :
    10/01/2027
    Completion :
    10/01/2027
    HER-2 • PD-L1 • AR
    |
    PD-L1 expression • HER-2 negative • AR positive
    |
    carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)
    Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) (NCT02000622)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/20/2025
    Initiation :
    03/27/2014
    Primary completion :
    12/09/2016
    Completion :
    12/31/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • capecitabine • Halaven (eribulin mesylate)
    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (MORAb-202-G000-201) (NCT04300556)
    Phase 1/2
    Eisai Inc.
    Recruiting
    Last update posted :
    12/09/2024
    Initiation :
    08/06/2020
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2 • BRAF • ER • ALK • PGR • ROS1
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone
    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) (NCT05824975)
    Phase 1/2
    GI Innovation, Inc.
    Recruiting
    Last update posted :
    11/25/2024
    Initiation :
    05/30/2023
    Primary completion :
    11/12/2025
    Completion :
    04/24/2027
    CD8 • CD4
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)
    Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) (NCT04711824)
    Phase 1/2
    Colette Shen
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    03/09/2022
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    HER-2 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (NCT02623972)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    02/26/2016
    Primary completion :
    05/01/2021
    Completion :
    12/01/2026
    HER-2
    |
    HER-2 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • Halaven (eribulin mesylate) • cyclophosphamide intravenous
    Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (EVER-132-002) (NCT04639986)
    Phase 3
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    11/23/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC) (NCT06072612)
    Phase 3
    BriaCell Therapeutics Corporation
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/05/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    ER • PGR
    |
    HER-2 negative
    |
    carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (NCT05041101)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/04/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • PGR • CD4
    |
    HER-2 positive • HER-2 negative
    |
    Halaven (eribulin mesylate) • grapiprant (RQ-00000007)
    Detect V / CHEVENDO (Chemo vs. Endo) (DETECT V) (NCT02344472)
    Phase 3
    Prof. Wolfgang Janni
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    09/01/2015
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    HER-2
    |
    HER-2 positive • HR positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (NCT03237780)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    07/20/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1 • CD4
    |
    PD-L1 expression
    |
    cisplatin • Tecentriq (atezolizumab) • Halaven (eribulin mesylate)
    DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (NCT02035813)
    Phase 2
    Prof. Wolfgang Janni
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    01/01/2014
    Primary completion :
    01/10/2024
    Completion :
    01/10/2024
    ER • PGR
    |
    ER positive • HR positive • HR negative • PGR positive
    |
    Kisqali (ribociclib) • Halaven (eribulin mesylate)
    PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA) (NCT05810870)
    Phase 2
    MedSIR
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    05/24/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2027
    PIK3CA • PTEN
    |
    PIK3CA mutation
    |
    Halaven (eribulin mesylate) • izorlisib (MEN1611)
    Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (NCT03202316)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    08/11/2017
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1 • ER • PGR
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)
    A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer (ARETHA) (NCT05570253)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/03/2022
    Primary completion :
    10/01/2027
    Completion :
    10/01/2027
    HER-2 • PGR
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • evexomostat (SDX-7320)
    Eribulin in HER2 Negative Metastatic BrCa (NCT01827787)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    05/15/2024
    Initiation :
    05/01/2013
    Primary completion :
    05/01/2016
    Completion :
    05/01/2016
    HER-2
    |
    HR positive • HER-2 negative • HR negative
    |
    Halaven (eribulin mesylate)
    A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (NCT05420779)
    Phase 2
    Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    06/30/2022
    Primary completion :
    12/31/2024
    Completion :
    06/30/2026
    HER-2 • BRCA
    |
    HR positive
    |
    capecitabine • Halaven (eribulin mesylate) • TSL1502
    A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (NCT05104866)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    10/18/2021
    Primary completion :
    08/15/2025
    Completion :
    08/15/2025
    HER-2
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan)
    Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (NCT03734029)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    04/11/2024
    Initiation :
    12/27/2018
    Primary completion :
    01/11/2022
    Completion :
    10/01/2025
    HER-2
    |
    HER-2 positive • HR positive • HER-2 expression
    |
    gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (NCT05374512)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    03/21/2024
    Initiation :
    05/16/2022
    Primary completion :
    12/03/2025
    Completion :
    12/03/2025
    HER-2 • PGR
    |
    PD-L1 expression • PD-L1 negative
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan)
    Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (NCT05458674)
    Phase 2
    Criterium, Inc.
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    01/01/2024
    Primary completion :
    06/01/2027
    Completion :
    08/01/2027
    HER-2
    |
    Herceptin (trastuzumab) • Halaven (eribulin mesylate) • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    DESTINY Breast Respond HER2-low Europe (NCT05945732)
    Phase N/A
    Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo C...
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    10/24/2023
    Primary completion :
    06/01/2027
    Completion :
    09/01/2028
    HER-2
    |
    HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (NCT03051659)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    03/06/2024
    Initiation :
    03/22/2017
    Primary completion :
    10/11/2018
    Completion :
    09/05/2023
    HER-2
    |
    HR positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    Study of E7389 Liposomal Formulation in Participants With Solid Tumor (E7389-J081-114) (NCT03207672)
    Phase 1
    Eisai Co., Ltd.
    Active, not recruiting
    Last update posted :
    03/01/2024
    Initiation :
    08/18/2017
    Primary completion :
    07/19/2018
    Completion :
    08/31/2025
    HER-2 • PD-L1
    |
    HER-2 negative • PD-L1 negative
    |
    Halaven (eribulin mesylate) • eribulin liposomal (E7389-LF)
    Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (SYSKY-2023-1016-01) (NCT06255392)
    Phase 3
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Not yet recruiting
    Last update posted :
    02/13/2024
    Initiation :
    02/01/2024
    Primary completion :
    03/01/2031
    Completion :
    03/01/2031
    BRCA
    |
    gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)
    Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01) (NCT05806060)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    04/25/2023
    Primary completion :
    08/31/2025
    Completion :
    02/28/2026
    HER-2
    |
    HER-2 expression • PGR expression
    |
    Avastin (bevacizumab) • carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate
    Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (BCTOP-T-M02) (NCT05760378)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    03/17/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • AiRuiKa (camrelizumab) • capecitabine • Halaven (eribulin mesylate) • famitinib (SHR 1020)
    SMMART Adaptive Clinical Treatment (ACT) Trial (NCT05238831)
    Phase 1
    OHSU Knight Cancer Institute
    Withdrawn
    Last update posted :
    01/23/2024
    Initiation :
    01/30/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • BRCA1 • BRCA2
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)
    Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (BCTOP-T-M03) (NCT05954442)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    09/13/2023
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    HER-2
    |
    carboplatin • everolimus • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA) (NCT06102824)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    01/20/2024
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    HER-2 • ER • PGR
    |
    HR positive • HER-2 negative • ER positive + PGR positive
    |
    carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
    Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) (NCT03901339)
    Phase 3
    Gilead Sciences
    Completed
    Last update posted :
    11/20/2023
    Initiation :
    05/08/2019
    Primary completion :
    10/20/2023
    Completion :
    10/20/2023
    HER-2
    |
    HR positive • HER-2 negative • EGFR positive
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER) (NCT04464174)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    11/15/2023
    Initiation :
    10/08/2020
    Primary completion :
    11/10/2023
    Completion :
    11/10/2023
    HER-2 • ER • PGR
    |
    ER expression
    |
    carboplatin • gemcitabine • capecitabine • Halaven (eribulin mesylate) • ipatasertib (RG7440)
    SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (NCT05347134)
    Phase 3
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Active, not recruiting
    Last update posted :
    10/20/2023
    Initiation :
    06/10/2022
    Primary completion :
    10/31/2023
    Completion :
    12/31/2024
    HER-2 • PGR • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP) (NCT03262935)
    Phase 3
    Byondis B.V.
    Completed
    Last update posted :
    10/19/2023
    Initiation :
    12/15/2017
    Primary completion :
    03/31/2021
    Completion :
    06/30/2022
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jivadco (trastuzumab duocarmazine)
    A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (SKB264-Ⅲ-10) (NCT06081959)
    Phase 3
    Sichuan Kelun Pharmaceutical Research Institute...
    Not yet recruiting
    Last update posted :
    10/13/2023
    Initiation :
    11/30/2023
    Primary completion :
    03/31/2026
    Completion :
    12/31/2027
    HER-2
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)